iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Biocon Biologics out-licenses two biosimilar assets to Yoshindo

17 Oct 2022 , 09:19 AM

Biocon Biologics Ltd., a Biocon Ltd. subsidiary, said today that it has entered into a strategic out-licensing agreement with Japanese pharmaceuticals business Yoshindo Inc. for the commercialization of two of its pipeline biosimilar assets, bUstekinumab and bDenosumab, in the Japanese market.

According to the terms of the agreement, Yoshindo will have exclusive marketing rights in Japan for Biocon Biologics' bUstekinumab and bDenosumab, for a USD 700 million# addressable market potential. Biocon Biologics will be paid an upfront licensing fee as well as future payments if specific development milestones are met over the following few years. The financial specifics of the arrangement are kept private.

Ustekinumab, a biosimilar of Stelara, is a monoclonal antibody that is used to treat psoriasis, Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Denosumab, a biosimilar to Prolia, is a monoclonal antibody used to treat osteoporosis.

Biocon Biologics' strategic agreement with Yoshindo will build on the company's significant accomplishments in its worldwide development programmes for these two biosimilar products. Clinical trials for these two assets began in FY22, and they include both Phase 1 and Phase 3 trials, as well as sophisticated pre-clinical CMC packages.

Biocon Biologics is creating a comprehensive portfolio of 20 biosimilar assets, either individually or through strategic alliances, to supply patients with affordable biologics and allow health equity.

At around 9.18 AM, Biocon was trading at Rs261.45 up by 0.06% from its previous closing of Rs261.30 on the BSE.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Biocon Biologics
  • Biocon news
  • Biocon results
  • Biocon Share
  • Biocon Stock
  • Biocon Updates
  • BioconSharePrice
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
29 Mar 2024   |   10:14 AM
Images
28 Mar 2024   |   03:36 PM
Images
28 Mar 2024   |   03:01 PM
Images
28 Mar 2024   |   01:21 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.